Stephen Basil Thomas Sells 100,000 Shares of Climb Bio (NASDAQ:CLYM) Stock

Posted by George Bondi on Sep 17th, 2026

Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) Director Stephen Basil Thomas sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the sale, the director directly owned 467,969 shares in the company, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Climb Bio Price Performance

Shares of NASDAQ:CLYM traded down $0.05 during trading on Thursday, hitting $14.06. 987,390 shares of the company were exchanged, compared to its average volume of 1,016,128. The firm’s 50 day moving average price is $14.28 and its 200-day moving average price is $11.31. Climb Bio, Inc. has a 12-month low of $1.54 and a 12-month high of $18.33. The stock has a market capitalization of $807.61 million, a P/E ratio of -16.94 and a beta of 0.09.

Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. As a group, equities research analysts anticipate that Climb Bio, Inc. will post -0.78 EPS for the current year.

Analyst Ratings Changes

CLYM has been the topic of a number of research analyst reports. Guggenheim assumed coverage on Climb Bio in a research report on Monday, June 8th. They set a “buy” rating and a $35.00 target price on the stock. Piper Sandler set a $40.00 target price on Climb Bio and gave the company an “overweight” rating in a research report on Thursday, September 3rd. Robert W. Baird raised their price target on Climb Bio from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Friday, July 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 price objective on shares of Climb Bio in a research note on Wednesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $26.92.

Check Out Our Latest Research Report on Climb Bio

Hedge Funds Weigh In On Climb Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in Climb Bio during the 2nd quarter worth $45,000. Spark Investment Management LLC acquired a new position in shares of Climb Bio during the second quarter worth about $177,000. State of Wyoming purchased a new position in Climb Bio during the second quarter worth about $187,000. Seven Fleet Capital Management LP purchased a new position in Climb Bio during the fourth quarter worth about $306,000. Finally, Bank of America Corp DE acquired a new stake in Climb Bio in the second quarter valued at about $335,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Climb Bio

(Get Free Report)

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research is centered on treatments intended to address conditions in which abnormal B-cell activity contributes to disease.

Climb Bio’s lead investigational program, CLYM-001, is a CD19-directed antibody designed to target and deplete B cells. The candidate is being developed for potential use in autoimmune and other immune-mediated disorders.